NCT05678348View on ClinicalTrials.gov

Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 3, 2023

Primary Completion Date

July 11, 2025

Study Completion Date

August 4, 2025

Conditions
Head and Neck CancerCancer of the Head and Neck
Interventions
DRUG

Pyrimethamine

Patients will be instructed to take their dose at approximately the same time each day.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Tilde Sciences

UNKNOWN

lead

Washington University School of Medicine

OTHER